2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22

Lucia Musacchio; Margherita Turinetto; Michele Bartoletti; Laura Arenare; Daniela Califano; Valentina Tuninetti; Gennaro Cormio; Carmela Pisano; Giorgio Valabrega; Claudia Marchetti; Sabrina Chiara Cecere; Stefano Greggi; Francesco Raspagliesi; Francesco Perrone; Anna Fagotti; Domenica Lorusso; Giovanni Scambia; Sandro Pignata

doi:10.1136/ijgc-2022-ESGO.759

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

Ovarian cancer

2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22

Free

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password